EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study

Shihan Zhou, Ru Yao, Mengqi Zhang, Mingxia Jiang, Jiaxuan Liu, Mingxiao Li, Fei Ma, Bo Pan, Qiao Li iD

Breast Cancer: Targets and Therapy · 2026-05 · Volume 18 · 1-13

DOI: 10.2147/bctt.s589939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer: Targets and Therapy, 2026-05. Verfasst von Shihan Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorHR+/HER2- breast cancercross-line therapydalpiciclibendocrine resistance

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of Ch…
  • Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.

ORCID-Profile: Qiao Li

Zitieren

APA

Zhou, S., Yao, R., Zhang, M., Jiang, M., Liu, J., Li, M., Ma, F., Pan, B., & Li, Q. (2026). Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study. Breast Cancer: Targets and Therapy, Volume 18, 1-13. https://doi.org/10.2147/bctt.s589939

Vancouver

Zhou S, Yao R, Zhang M, Jiang M, Liu J, Li M, et al. Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study. Breast Cancer: Targets and Therapy. 2026;Volume 18:1-13. doi:10.2147/bctt.s589939

BibTeX
@article{Zhou2026,
  author = {Zhou, Shihan and Yao, Ru and Zhang, Mengqi and Jiang, Mingxia and Liu, Jiaxuan and Li, Mingxiao and Ma, Fei and Pan, Bo and Li, Qiao},
  title = {Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study},
  journal = {Breast Cancer: Targets and Therapy},
  year = {2026},
  volume = {Volume 18},
  pages = {1--13},
  doi = {10.2147/bctt.s589939}
}
Kostenlos starten →